Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma
Liver Cancer · 16.06.2026 · 1-14
DOI: 10.1159/000553049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 16.06.2026. Verfasst von Jinho Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
While immunotherapy has emerged as a promising treatment option, no reliable predictive biomarker has been established for immunotherapy in hepatocellular carcinoma (HCC). In this study, we used genetic analyses to verify the prognostic significance of tumor mutation burden (TMB) in HCC and to search for other cancer characteristics related to prognosis.
Methods
Patients with HCC who received a combined therapy of atezolizumab and bevacizumab were prospectively enrolled between July 2020 and April 2023. Circulating tumor DNA analysis was performed using next-generation sequencing before immunotherapy (baseline) and 3 weeks after initiation of immunotherapy (follow-up), from which we retrieved non-synonymous baseline, follow-up, vanished (detected only at baseline), and acquired (detected only at follow-up) variants. Gene sets related to cancer hallmarks and representative oncogenic pathways were curated.
Results
Forty-two patients were enrolled in this study. Higher TMB was not correlated with better prognosis. Instead, it showed an inverse relationship, with higher baseline TMB significantly associated with shorter progression-free survival (PFS) (median 2.73 vs. 9.17 months, p = 0.04). Among other cancer characteristics, acquired variants in the Wnt/β-catenin (PFS: p = 1.14 × 10−4; overall survival [OS]: p = 0.004) and ATP-dependent chromatin remodeling (PFS: p = 0.002; OS: p = 0.006) pathways were significantly correlated with worse prognosis.
Conclusion
In HCC, TMB is not a reliable predictive biomarker for immunotherapy. Instead, the emergence of acquired genetic variants in the Wnt/β-catenin and chromatin remodeling pathways act as a key driver of resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea.
- Department of Laboratory Medicine, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Dxome Co., Ltd., Seongnam, Republic of Korea.
Zitieren
APA
Lee, J., Lee, H. W., Park, M. R., Shin, S., Choi, J. R., Park, H. J., Cho, K. J., Lee, S. T., & Park, J. Y. (2026). Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma. Liver Cancer, 1-14. https://doi.org/10.1159/000553049
Vancouver
Lee J, Lee HW, Park MR, Shin S, Choi JR, Park HJ, et al. Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma. Liver Cancer. 2026:1-14. doi:10.1159/000553049
BibTeX
@article{Lee2026,
author = {Lee, Jinho and Lee, Hye Won and Park, Mi Ri and Shin, Saeam and Choi, Jong Rak and Park, Hye Jung and Cho, Kyung Joo and Lee, Seung-Tae and Park, Jun Yong},
title = {Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma},
journal = {Liver Cancer},
year = {2026},
pages = {1--14},
doi = {10.1159/000553049}
}
EUVIMED